US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Champion Industries, Inc.

0.0001

+0.0000

Volume:- -

Turnover:- -

Market Cap:5.59

PE:0.00

High:0.0001

Open:0.0001

Low:0.0001

Close:0.0001

Loading ...

Overview Company News Filings

Press Release: Pharming Group reports first quarter 2025 financial results and provides business update

Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?

Vertex Reports First Quarter 2025 Financial Results

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

Astrazeneca's Fixed-Duration Calquence-Based Regimen Receives CHMP Recommendation for Leukaemia

MT Newswires Live

Cosmo Pharmaceuticals Maintains 2025 Financial Forecast Amid CHMP Statement on Winlevi®

Cosmo Pharmaceuticals Confirms Financial Guidance Following CHMP Opinion on Winlevi(R)

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Camurus Receives CHMP Recommendation for Potential Drug to Treat Rare Disease Caused by Pituitary Gland Tumor

MT Newswires Live

CHMP gives positive opinion on marketing authorization variation for Amvuttra

CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU

PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHMP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"Champion Industries, Inc.","latestPrice":0.0001,"timestamp":1746818220000,"preClose":0.0001,"halted":0,"volume":0,"delay":15,"floatShares":0,"shares":55857,"eps":-23.033406,"marketStatus":"Trading","change":0,"latestTime":"05-09 15:17:00 EDT Delay","open":0.0001,"high":0.0001,"low":0.0001,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033406,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746820800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.0001,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","floatShares":0,"roa":"-1.87%","roe":"-49.45%","lyrEps":-23.033406,"shares":55857,"dividePrice":0,"high":0.0001,"amplitude":0,"preClose":0.0001,"low":0.0001,"week52Low":0.0001,"pbRate":"0.00","psRate":"0.00","week52High":0.0001,"institutionHeld":0,"latestPrice":0.0001,"eps":-23.033406,"divideRate":0,"volume":0,"delay":15,"ttmEps":-23.033406,"open":0.0001,"prevYearClose":0.0001,"prevWeekClose":0.0001,"prevMonthClose":0.0001,"prevQuarterClose":0.0001,"fiveDayClose":0.0001,"twentyDayClose":0.0001,"sixtyDayClose":0.0001},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHMP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533944978","title":"Press Release: Pharming Group reports first quarter 2025 financial results and provides business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2533944978","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533944978?lang=en_us&edition=fundamental","pubTime":"2025-05-08 13:00","pubTimestamp":1746680400,"startTime":"0","endTime":"0","summary":"-- First quarter 2025 total revenues increased by 42% to US$79.1 million,-- RUCONEST revenue increased by 49% to US$68.6 million, compared to the. first quarter 2024, reflecting continued momentum and the product's. -- Joenja  volume increase by 18% and revenue increased by 9%. to US$10.5 million, compared to the first quarter of 2024, with. accelerating patient uptake compared to the prior few quarters. acquisition-related expenses, amounted to US$0.8 million compared to a. -- Launched Joenja  in England and Wales in April and. preparing to file for U.S. FDA approval for pediatrics in the third. We are making strong progress advancing high value programs in our pipeline.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","EEA","BK4023","CHMP","BK4588","ODD","BK4022","PHAR","BK4585","R","BK4543","BK4215","IE00BFMHRM44.USD","BK4087","NICE","BK4232","BK4566","BK4139","MAA"],"gpt_icon":0},{"id":"2533425671","title":"Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2533425671","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533425671?lang=en_us&edition=fundamental","pubTime":"2025-05-07 16:49","pubTimestamp":1746607740,"startTime":"0","endTime":"0","summary":"Vertex missed Wall Street's Q1 estimates and announced a pause with an early-stage study of its mRNA cystic fibrosis drug.However, the big drugmaker had plenty of good news in its Q1 update, too.This biotech stock should still generate exceptional returns over the next few years.Vertex Pharmaceuticals'  remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. However, Vertex's shares plunged after the company announced its first-quarter results on Monday.Should investors throw in the towel on Vertex?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/07/why-vertex-pharmaceuticals-stock-is-a-screaming-bu/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["CHMP","LU0256863811.USD","LU0061475181.USD","LU0823416689.USD","IE00B19Z3B42.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0889565916.HKD","LU2463526074.USD","LU0079474960.USD","IE00B2B36J28.USD","LU1481600234.SGD","BK4567","IE00B894F039.SGD","BK4093","LU0320765992.SGD","LU1169589451.USD","LU1169590202.USD","LU1585245621.USD","IE00B4R5TH58.HKD","LU0757428866.USD","IE0009355771.USD","LU2362540622.SGD","LU2362541273.HKD","LU0566484027.USD","LU1559883803.SGD","BK4139","SG9999001176.SGD","VERX","IE0002270589.USD","BK4532","BK4533","LU2362541513.USD","LU2236285917.USD","LU0109394709.USD","IE00B19Z9Z06.USD","LU2324357040.USD","LU2462157665.USD","SGXZ57979304.SGD","CF","LU2417539215.USD","VRTX","LU1430594728.SGD","LU1487256676.USD","IE00B3T34201.USD","IP","LU0289739699.SGD","LU2456880835.USD","LU0417517546.SGD","LU1093756168.USD"],"gpt_icon":0},{"id":"2533650385","title":"Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?","url":"https://stock-news.laohu8.com/highlight/detail?id=2533650385","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533650385?lang=en_us&edition=fundamental","pubTime":"2025-05-06 04:54","pubTimestamp":1746478460,"startTime":"0","endTime":"0","summary":"PTC Therapeutics, Inc.  on Monday announced results from the Phase 2 PIVOT-HD study of PTC518  in Stage 2 and Stage 3 Huntington’s disease  patients.Huntington’s disease isa progressive neurodegenerative disorder caused by mutation of thehuntingtin gene, leading to the breakdown of brain cells.It is characterized by uncontrolled movements , cognitive decline, and psychiatric disturbances.The study met its primary endpoint of reduction in blood Huntingtin  protein levels  at Week 12 and favorable safety and tolerability. In addition, the 12-month data from the Stage 2 patients are consistent with the previously reported dose-dependent lowering of HTT protein and dose-dependent trends across clinical scales.“We look forward to discussions on the next development and regulatory steps, including the potential for accelerated approval as we work to potentially bring the first disease-modifying therapy...,” saidMatthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics.Price Action: P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-did-ptc-therapeutics-stock-205420825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1951198990.SGD","LU0320765646.SGD","LU0354030438.USD","LU2477742899.HKD","LU0689472784.USD","BK4550","LU2506952337.HKD","LU2756315318.SGD","LU0889565916.HKD","LU0109394709.USD","LU1551013425.SGD","HD","BK4576","IE00BWXC8680.SGD","LU0943347566.SGD","LU2237438978.USD","TFC","LU0820561909.HKD","PTC","LU0823434583.USD","LU1496350171.SGD","BK4554","LU1035775433.USD","CHMP","PTCT","LU1923623000.USD","SG9999001440.SGD","LU1069344957.HKD","LU1674673428.USD","LU1951200564.SGD","BK4087","LU2362541513.USD","LU1929549753.HKD","BK4585","LU0820562030.AUD","BK4566","LU1093756168.USD","IE00BSNM7G36.USD","LU1914381329.SGD","SSI","BK4083","LU2756315664.SGD","LU0320765992.SGD","IE00B1XK9C88.USD","LU0234572021.USD","LU1551013342.USD","LU2506952410.USD","LU1721428347.USD","BK4023","LU1778281490.HKD"],"gpt_icon":0},{"id":"2533568415","title":"Vertex Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2533568415","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533568415?lang=en_us&edition=fundamental","pubTime":"2025-05-06 04:01","pubTimestamp":1746475260,"startTime":"0","endTime":"0","summary":"— Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion —。— Strong progress with CASGEVY, ALYFTREK and JOURNAVX launches —。— Povetacicept  IgAN Phase 3 interim analysis  cohort fully enrolled and zimislecel Phase 3 program to complete dosing this quarter, setting up potential filings in 2026; inaxaplin Phase 3 IA cohort on track to complete enrollment in the second half of 2025 —。— Four programs already in pivotal development, with pivotal study of pove in primary membranous nephropathy  to start this year —。Combined GAAP and Non-GAAP R&D, Acquired IPR&D and SG&A expenses were $1.4 billion and $1.2 billion, respectively, compared to $1.2 billion and $1.0 billion, respectively, in the first quarter of 2024. The increases were primarily due to continued R&D investment in support of multiple mid- and late-stage clinical development programs and increased commercial investment ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vertex-reports-first-quarter-2025-200100412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B894F039.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","KSA","SCD","IE00BJT1NW94.SGD","UAE","LU1559883803.SGD","SG9999001176.USD","CF","BK4588","LU1093756168.USD","LU2324357040.USD","BK4093","PBM","VERX","CHMP","IE00BJJMRZ35.SGD","LU0109394709.USD","LU0320765992.SGD","IE0002141913.USD","LU0234570918.USD","SG9999001176.SGD","VTNR","BK4139","LU1035775433.USD","BK4567","BK4585","LU2362541513.USD","LU0889565916.HKD","LU0061475181.USD","LU1815336091.USD","IE00B19Z9Z06.USD","LU2237438978.USD","VRTX","BK4138","IE0009355771.USD","LU0289739699.SGD","SGXZ57979304.SGD","IE0002270589.USD","LU1430594728.SGD","SG9999013999.USD","LU2456880835.USD","BK4533","BK4532","IE00B19Z3581.USD","BK4087","LU1093756325.SGD"],"gpt_icon":0},{"id":"2532872260","title":"Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2532872260","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532872260?lang=en_us&edition=fundamental","pubTime":"2025-05-03 05:04","pubTimestamp":1746219890,"startTime":"0","endTime":"0","summary":"Alnylam analysts highlight Amvuttra&#39;s strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/05/45179856/alnylam-delivers-q1-surprise-analysts-highlight-amvuttra-momentum-and-limited-tariff-risk","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","BK4505","BK4585","BK4139","CHMP","BK4548","ALNY","BBIO","BK4588"],"gpt_icon":0},{"id":"2532071224","title":"Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2532071224","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532071224?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:00","pubTimestamp":1746100800,"startTime":"0","endTime":"0","summary":"Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year-Over-Year Growth Compared to Q1 2024 Driven by Continued Strong Growth of 36% from hATTR-PN Franchise –。Received U.S. Food and Drug Administration  Approval of AMVUTTRA  to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy  –。AMVUTTRA ATTR-CM Launch Underway with Strong Progress Across All Early Commercial Indicators –。Approval of Qfitlia Represents the First and Only Therapeutic to Treat Hemophilia A or B With or Without Inhibitors and the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA –。Reiterates 2025 Financial Guidance, Including Combined Net Product Revenues of $2,050 Million to $2,250 Million –。CAMBRIDGE, Mass., May 01, 2025----Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended Mar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-pharmaceuticals-reports-first-quarter-120000897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GO","BK4097","LU2065732104.USD","CHMP","ALNY","BK4548","LU0471298777.SGD","LU0385154629.USD","BK4087","PRGS","BK4588","BK4113","AHP","BK4139","BK4585"],"gpt_icon":0},{"id":"2531759246","title":"Astrazeneca's Fixed-Duration Calquence-Based Regimen Receives CHMP Recommendation for Leukaemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2531759246","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531759246?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:41","pubTimestamp":1745937700,"startTime":"0","endTime":"0","summary":"Astrazeneca  said Tuesday its Calquence fixed-duration regimen was recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use to treat adults with previously untreated chronic lymphocytic leukaemia.CHMP's positive opinion was based on a phase 3 trial that indicated that Calquence combinations with venetoclax and obinutuzumab showed improved progression-free survival compared with chemoimmunotherapy, according to a statement.Shares were up 0.6% in recent trading.Price: 70.38, Change: +0.45, Percent Change: +0.64","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4568","BK4588","BK4007","LU2236285917.USD","CHMP","LU1829250122.USD","AZN","LU2417539215.USD","LU2462157665.USD","BK4585","LU0109394709.USD","LU0320765992.SGD","LU2456880835.USD","LU0889565916.HKD","BK4087"],"gpt_icon":0},{"id":"2531370407","title":"Cosmo Pharmaceuticals Maintains 2025 Financial Forecast Amid CHMP Statement on Winlevi®","url":"https://stock-news.laohu8.com/highlight/detail?id=2531370407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531370407?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:32","pubTimestamp":1745933541,"startTime":"0","endTime":"0","summary":"COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) has provided an update. Cosmo Pharmaceuticals has confirmed its financial forecast for 2025 remains uncha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cosmo-pharmaceuticals-maintains-2025-financial-forecast-amid-chmp-statement-on-winlevi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cosmo-pharmaceuticals-maintains-2025-financial-forecast-amid-chmp-statement-on-winlevi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4087","CHMP"],"gpt_icon":0},{"id":"2531732393","title":"Cosmo Pharmaceuticals Confirms Financial Guidance Following CHMP Opinion on Winlevi(R)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531732393","media":"Newsfile","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531732393?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:11","pubTimestamp":1745932260,"startTime":"0","endTime":"0","summary":"Dublin, Ireland-- - Following the recent CHMP opinion regarding the marketing authorization application for Winlevi  in Europe, Cosmo Pharmaceuticals N.V.  confirms that its financial guidance for 2025 remains unchanged.While the company is disappointed by the opinion, it maintains strong confidence in the clinical profile of Winlevi and its potential to address a significant unmet need in dermatology. The outcome of the CHMP opinion is not expected to have any material impact on the company’s current financial expectations.The Cosmo team is already preparing the re-examination submission. The company remains fully committed to securing access to Winlevi for patients in Europe.Cosmo will provide updates as the re-examination process progresses.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cosmo-pharmaceuticals-confirms-financial-guidance-131100893.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cosmo-pharmaceuticals-confirms-financial-guidance-131100893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHMP","BK4087","BK4022","BK4007","BK4232","CMOPF","R","USA"],"gpt_icon":0},{"id":"2531736587","title":"Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2531736587","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531736587?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928000,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., April 29, 2025  -- Madrigal Pharmaceuticals, Inc. , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis , today announced six presentations at the upcoming European Association for the Study of the Liver  Congress, taking place from May 7-10, 2025, in Amsterdam, the Netherlands. Madrigal will share detailed two-year data from the open-label compensated MASH cirrhosis  arm of the Phase 3 MAESTRO-NAFLD-1 trial in a late-breaking oral presentation titled, “Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis.”Resmetirom is not approved in Europe for the treatment of patients with MASH with moderate to advanced liver fibrosis and not approved in any geography for the treatme","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/madrigal-present-breaking-resmetirom-data-120000402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4096","BK4156","THR","BK4139","MDGL","BK4215","BK4585","MAA","BK4588","BK4087","CHMP"],"gpt_icon":0},{"id":"2531781941","title":"Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531781941","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531781941?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:01","pubTimestamp":1745924460,"startTime":"0","endTime":"0","summary":"European Commission converts conditional approval of FILSPARI into standard marketing authorization for the treatment of IgAN. EU approval is based on the complete data set from the Phase 3 PROTECT Study. The UK’s MHRA also converts the conditional approval of FILSPARI to standard approval. The European Commission's decision follows the Committee for Medicinal Products for Human Use  recommendation from February 2025 to convert the CMA to standard MA. The approval is based on a comprehensive clinical data set, including positive confirmatory results from the pivotal Phase 3 PROTECT Study demonstrating that FILSPARI significantly slowed kidney function decline over two years compared to irbesartan.In the UK, the Medicines and Healthcare products Regulatory Agency  converted the conditional FILSPARI approval to standard approval as of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/travere-therapeutics-csl-vifor-announce-110100458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2106854487.HKD","IE0004086264.USD","TVTX","LU0345769128.USD","LU0820561818.USD","LU2543165471.USD","LU2054465674.USD","LU1670627923.USD","LU2462157665.USD","CHMP","ETAR","LU0494093205.USD","LU0056508442.USD","LU0289941410.SGD","LU0109392836.USD","IE0004445239.USD","GB00BDT5M118.USD","BK4207","LU0823421416.USD","BK4106","CMA","LU0353189763.USD","LU0964807845.USD","LU1084165304.USD","IE00B775H168.HKD","SGXZ51526630.SGD","LU0390134368.USD","LU0107464264.USD","LU1551013425.SGD","CSL","BK4548","LU0256863811.USD","SGXZ99366536.SGD","LU0985320562.USD","LU2764263039.SGD","LU0011850046.USD","LU0053666078.USD","LU0316494557.USD","BK4566","BK4581","IE0004091025.USD","SMP","BK4589","BK4585","ARB","LENZ","LU1983260115.SGD","MA","LU0109391861.USD"],"gpt_icon":0},{"id":"2530140961","title":"Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2530140961","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530140961?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"Recommended Approval Based on the Pivotal HELIOS-B Phase 3 Study in which Vutrisiran Demonstrated Significant Reductions in Mortality and Cardiovascular Events, While Preserving Functional Status and Quality of Life –。Offers a Clinically Differentiated Approach with Rapid and Sustained Transthyretin  Knockdown and Quarterly Subcutaneous Dosing –。European Commission Decision Expected in June 2025 –。The CHMP opinion was based on positive results from the pivotal HELIOS-B Phase 3, randomized, double-blind, placebo-controlled multicenter global study, which met all 10 of its pre-specified primary and secondary endpoints across both the overall and monotherapy populations. The findings demonstrated the benefits of vutrisiran on outcomes of mortali","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-receives-positive-chmp-opinion-120000497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4087","BK4139","CHMP","BK4156","BK4588","ALNY","BK4548","BK4585"],"gpt_icon":0},{"id":"2530470411","title":"Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2530470411","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530470411?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:30","pubTimestamp":1745839800,"startTime":"0","endTime":"0","summary":"European Commission  decision on marketing authorization application expected within approximately two months. SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc.   today announced thatargenx received a positive opinion from the Committee for Medicinal Products for Human Use  of the European Medicines Agency recommending European Commission  approval of VYVGART 1000mg  developed with ENHANZE, Halozyme's proprietary recombinant human hyaluronidase enzyme  for subcutaneous  injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy  after prior treatment with corticosteroids or immunoglobulins.VYVGART is the first and only targeted IgG Fc-antibody fragment for Chronic Inflammatory Demyelinating Polyneuropathy and the first novel mechanism of action for CIDP treatment in more than 30 years.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/halozyme-announces-argenx-received-positive-113000730.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/halozyme-announces-argenx-received-positive-113000730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HALO","BK4201","BK4139","LU0053671581.USD","BK4087","EC","CHMP"],"gpt_icon":0},{"id":"2530844822","title":"Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2530844822","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530844822?lang=en_us&edition=fundamental","pubTime":"2025-04-28 14:13","pubTimestamp":1745820780,"startTime":"0","endTime":"0","summary":"– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion  –。– Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business –。– SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas –。– Planned acquisition will strengthen the presence of Merck KGaA, Darmstadt, Germany’s Healthcare business in the United States and expand reach of SpringWorks' therapeutic innovations to more patients with rare tumors worldwide –。Upon closing, the business combination will immediately contribute to Merck KGaA, Darmstadt, Germany’s reve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-kgaa-darmstadt-germany-acquire-061300678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1066051498.USD","LU0234572021.USD","LU1571399168.USD","LU2361044949.HKD","LU2023250504.SGD","AAQC","MAA","IE00BFTCPJ56.SGD","SG9999014575.USD","LU1069347547.HKD","LU0122379950.USD","LU0861579265.USD","SG9999001176.USD","MRK","LU1929549753.HKD","SWTX","LU0238689110.USD","LU1023059063.AUD","LU0006306889.USD","LU1989772840.SGD","LU1989772923.USD","SG9999002232.USD","SG9999013999.USD","IE00BLSP4239.USD","LU0985320562.USD","CHMP","LU2361045086.USD","LU1917777945.USD","SG9999015341.SGD","IE00BJJMRZ35.SGD","LU1941712348.USD","LU1585245621.USD","PN","LU1162221912.USD","BK4137","LU1066053197.SGD","BK4007","IE00BJT1NW94.SGD","LU0203347892.USD","LU0965509283.SGD","HCSG","IE00B4R5TH58.HKD","LU2089984988.USD","LU2361044865.SGD","LU1093756325.SGD","LU2468319806.SGD","LENZ","LU0106261372.USD","LU1037948541.HKD","IE0002141913.USD"],"gpt_icon":0},{"id":"2530700414","title":"argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2530700414","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530700414?lang=en_us&edition=fundamental","pubTime":"2025-04-28 13:00","pubTimestamp":1745816400,"startTime":"0","endTime":"0","summary":"VYVGART is first-and-only targeted IgG Fc-antibody fragment for CIDP. First novel mechanism of action for CIDP treatment in more than 30 years. CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial. European Commission  decision on marketing authorization application expected within approximately two months. “Our mission is to develop innovative, targeted treatments for patients with rare and severe autoimmune diseases, who continue to face significant unmet needs. The positive CHMP opinion for VYVGART in CIDP brings us one step closer to providing patients across Europe with a transformational new treatment option that provides meaningful functional improvement,” said Luc Truyen M.D., Ph.D., Chief Medical Officer, argenx. “VYVGART is the first and only targeted IgG Fc-antibody fragment for CIDP and if approved, would mark the first treatment in Europe with a novel, precision mechanism of action for CIDP patients in 30 years.”\"For the patient population repre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenx-announces-positive-chmp-opinion-050000869.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARGNF","BK4201","ARGX","CHMP","MAA","BK4585","BK4588","BK4087","BK4215","EC","BK4139"],"gpt_icon":0},{"id":"2530115238","title":"Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530115238","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530115238?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:27","pubTimestamp":1745594820,"startTime":"0","endTime":"0","summary":"DUBLIN, April 25, 2025 /PRNewswire/ --Jazz Pharmaceuticals plc  today announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency  has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth factor receptor 2 -targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive  biliary tract cancer  previously treated with at least one prior line of systemic therapy.1. \"This positive CHMP opinion is a welcome step for physicians and patients in Europe who face a critical unmet need in HER2-positive biliary tract cancers, a rare and aggressive group of cancers with poor prognosis and limited treatment options,\" said Robert Iannone, MD., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals. \"If approved, zanidatamab would b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-receives-chmp-positive-152700121.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-receives-chmp-positive-152700121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4087","BK4156","IE00B7SZL793.SGD","CDC","BTC","LU0823416689.USD","BK4157","LU0109394709.USD","IE00BN0W2T93.GBP","IE0031619046.USD","BK4532","BK4007","BK4533","CHMP","IE00B66KJ199.SGD","IE00BN0W2V16.EUR","JAZZ","IE00BN0W2W23.USD","LU0889565916.HKD","HCC","BK4006","CCA","AEIS","IE00B19Z4B17.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2530615372","title":"Camurus Receives CHMP Recommendation for Potential Drug to Treat Rare Disease Caused by Pituitary Gland Tumor","url":"https://stock-news.laohu8.com/highlight/detail?id=2530615372","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530615372?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:08","pubTimestamp":1745593680,"startTime":"0","endTime":"0","summary":"Camurus  said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of Oczyesa to treat patients with acromegaly, a disease stemming from the pituitary gland.CHMP's positive opinion is backed by seven clinical trials of the potential drug, which showcased a \"higher proportion\" of patients who responded to treatment with somatostatin analogues, achieving normalized insulin growth-factor-1 levels versus placebo groups, the company said.One of the studies also showed improvement in symptoms and quality of life, according to a statement.The company said a final decision on the market authorization is expected from the European Commission mid-year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CHMP","CAMX","BK4087"],"gpt_icon":0},{"id":"2530130974","title":"CHMP gives positive opinion on marketing authorization variation for Amvuttra","url":"https://stock-news.laohu8.com/highlight/detail?id=2530130974","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530130974?lang=en_us&edition=fundamental","pubTime":"2025-04-25 22:26","pubTimestamp":1745591177,"startTime":"0","endTime":"0","summary":"The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending a change to the terms of the marketing authorizat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/chmp-gives-positive-opinion-on-marketing-authorization-variation-for-amvuttra?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/chmp-gives-positive-opinion-on-marketing-authorization-variation-for-amvuttra?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4087","CHMP"],"gpt_icon":0},{"id":"2530137383","title":"CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2530137383","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530137383?lang=en_us&edition=fundamental","pubTime":"2025-04-25 22:15","pubTimestamp":1745590500,"startTime":"0","endTime":"0","summary":"LUND, Sweden, April 25, 2025 /PRNewswire/ -- Camurus  today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use  has adopted a positive opinion for market authorization of Oczyesa, octreotide subcutaneous depot , for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.1. \"We are pleased with the CHMP's positive recommendation for market authorization for Oczyesa octreotide monthly depot for the treatment of acromegaly\", says Fredrik Tiberg, President & CEO at Camurus. \"Oczyesa has the potential to advance the standard of care for patients living with acromegaly by enhancing octreotide plasma exposure and enabling easy and convenient once-monthly self-administration by patients using an autoinjector pen.\". Fredrik Joabsson, Chief Business Development OfficerTel. +46 70 776 17 37ir@camurus.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/chmp-recommends-approval-oczyesa-treatment-141500893.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chmp-recommends-approval-oczyesa-treatment-141500893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAMRF","BK4171","BK4567","BK4007","BK4087","PLD","CHMP","BK4156","BK4585","BK4588","BK4534","BK4224"],"gpt_icon":0},{"id":"2530135824","title":"PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2530135824","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530135824?lang=en_us&edition=fundamental","pubTime":"2025-04-25 21:00","pubTimestamp":1745586000,"startTime":"0","endTime":"0","summary":"WARREN, N.J., April 25, 2025 /PRNewswire/ -- PTC Therapeutics, Inc.  announced today that the Committee for Medicinal Products for Human Use  of the European Medicines Agency  has issued a positive opinion on the marketing authorization application for Sephience  for the treatment of children and adults living with phenylketonuria . The opinion includes a broad label inclusive of all ages and disease severities.\"This positive opinion is great news for the PKU patient community in Europe for whom there remains a significant unmet medical need,\" saidMatthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. \"We look forward to initiating the European launch immediately following the adoption of this positive opinion by the European Commission. The data collected to date continue to support the potential for Sephience to provide a safe and effective treatment that not only lowers phenylalanine levels but also enables diet liberalization even for those with the most severe diseas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ptc-therapeutics-receives-positive-chmp-130000306.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ptc-therapeutics-receives-positive-chmp-130000306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4554","BK4576","LU2362541513.USD","BK4139","LU1951200564.SGD","LU1923623000.USD","BK4588","LU0320765992.SGD","LU1721428347.USD","BK4585","LU1951198990.SGD","LU2362540622.SGD","LU0109394709.USD","LU2477742899.HKD","PTCT","PTC","BK4023","LU2506952337.HKD","BK4087","LU2506952410.USD","CHMP","LU0889565916.HKD","LU2362541273.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":127,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHMP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHMP\",market:\"US\",delay:false,,,undefined,":{}}}